Whole Tumor Lysate DC Vaccine Construction & Fusion Platform

Q: What undefined antigen formats do you support for cancer vaccine development?

We support a full range of undefined antigen formats: whole irradiated tumor cells (autologous or allogeneic), tumor cell lysates (freeze-thaw, sonication, oncolysate), heat shock protein-peptide complexes (gp96, HSP70), tumor-derived exosomes, and DC-tumor fusion cells. Each format has distinct immunological advantages, and we can help you select the optimal approach based on your tumor type and study objectives.

Q: Why is tumor cell conditioning important before lysate preparation?

Unconditioned tumor lysates often lack sufficient danger signals for effective DC activation. Conditioning through heat shock, hypochlorous acid treatment, or controlled irradiation induces immunogenic cell death (ICD), triggering the release of DAMPs such as calreticulin, HMGB1, and ATP. These molecules serve as natural adjuvants that promote DC maturation, antigen update, and cross-priming, significantly enhancing vaccine immunogenicity compared to unconditioned lysate preparations.

Q: Can you develop undefined antigen vaccines for both mouse and human models?

Yes. We prepare undefined antigen vaccines for syngeneic mouse models (using mouse tumor cell lines and bone marrow-derived DCs) and for human systems (using patient-derived or allogeneic tumor cells with monocyte-derived DCs). Our humanized mouse models enable evaluation of human-specific immune responses to undefined antigen preparations in an in vivo setting.

Q: What adjuvants do you recommend for undefined antigen-based vaccines?

Adjuvant selection depends on the antigen format and tumor type. For whole cell or lysate vaccines, TLR agonists (CpG for TLR9, poly(I:C) for TLR3, imiquimod for TLR7) and saponin-based QS-21 are commonly used to enhance Th1 and CD8+ T cell responses. For DC-loaded vaccines, the DAMPs inherent in ICD-conditioned preparations often provide intrinsic adjuvanticity, though we may supplement with haemocyanin carriers or cytokine adjuvants (GM-CSF) depending on the formulation strategy.

Q: What is the advantage of DC-tumor fusion cells over lysate-pulsed DCs?

DC-tumor fusion cells combine the entire antigen-processing and co-stimulatory machinery of professional APCs with the complete antigen repertoire of tumor cells in a single hybrid cell. Unlike lysate-pulsed DCs, where antigens must be taken up and processed ex vivo, fusion cells continuously synthesize and present tumor antigens endogenously through both MHC-I and MHC-II pathways, providing sustained and coordinated CD4+ and CD8+ T cell activation. HSP70 peptide complexes isolated from fusion cells also carry elevated tumor antigen cargo compared to those from unfused cells.

For many common malignancies, particularly carcinomas of epithelial origin, the full spectrum of tumor antigens remains incompletely characterized. Undefined antigen-based vaccines address this gap by harnessing whole tumor cells or their derivatives—lysates, exosomes, and heat shock protein (HSP) complexes—as antigenic sources. Unlike defined-antigen approaches that target single epitopes, these preparations deliver a broad repertoire of both shared tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs), including neoantigens that the host may not have encountered. Creative Biolabs offers a comprehensive preclinical development platform covering every stage of undefined antigen vaccine production, from tumor cell conditioning and lysate optimization through DC loading, adjuvant formulation, and in vivo efficacy validation, ensuring that each vaccine candidate delivers the broadest possible antigenic coverage for robust polyclonal T cell activation.

Why Choose Undefined Antigen Sources for Cancer Vaccines?

The Advantage of Antigen Breadth

Undefined antigen preparations preserve the natural heterogeneity of tumor cells. Whole tumor cell (WTC) vaccines and their derivatives—lysates, HSP complexes, and exosomes—contain both TAAs and TSAs, reducing the risk of tumor immune escape through antigen loss. This multi-target strategy ensures that even if one antigen is downregulated, the immune system can still recognize and attack the tumor through alternative epitopes, a critical advantage over single-antigen approaches.

Key Immunological Benefit:
Whole tumor lysate-pulsed DC vaccines have been shown to outperform peptide vaccines based solely on in silico-predicted neoantigens in controlling tumor growth across multiple preclinical models, underscoring the value of comprehensive antigen coverage.

Core Preclinical Challenges We Address:
Optimizing tumor cell conditioning to enhance immunogenicity (ICD/DAMP release).
Selecting the optimal antigen preparation format (lysate vs. HSP vs. exosome vs. whole cell).
Achieving efficient DC loading and cross-presentation of undefined antigens.
Overcoming immune tolerance to self-antigens present in undefined preparations.

Undefined vs. Defined Antigen Vaccine Strategies

Key Comparison	Defined Antigen Vaccines	Undefined Antigen-Based Vaccines
Antigen Coverage	Limited to pre-selected epitopes; risk of antigen escape.	Broad repertoire of TAAs + TSAs; reduces immune escape.
Antigen Discovery Requirement	Requires prior identification of immunogenic epitopes.	No prior antigen identification needed; ideal for poorly characterized tumors.
T Cell Response Breadth	Typically biased toward single epitope-specific clones.	Polyclonal CD4+ and CD8+ T cell activation with epitope spreading.
Applicability	Limited to tumors with well-characterized antigens.	Applicable to any tumor type, including poorly characterized carcinomas.

End-to-End Undefined Antigen Vaccine Service Modules

Our preclinical services span the entire undefined antigen vaccine development pipeline. Each module is fully customizable—from antigen preparation method to adjuvant selection—to align with your tumor model, species requirements, and research objectives.

Preparation

Tumor Cell Conditioning & Antigen Preparation

Preparing immunogenic whole tumor cells and cell-derived materials with optimized stress conditioning.

Cell Lysate Preparation: Freeze-thaw cycles, sonication, or oncolysate methods with controlled protein quantification.
ICD Induction: Heat shock, hypochlorous acid treatment, or irradiation to trigger DAMP release (CRT, HMGB1, ATP).
HSP Complexes: Purification of tumor-derived HSP-peptide complexes (gp96, HSP70) for cross-priming.
Exosome Isolation: Ultracentrifugation or polymer-based purification of tumor-derived exosomes with antigen and HSP cargo.

Engineering

Gene-Modified Tumor Cell Vaccines

Engineering tumor cells to secrete immunomodulatory molecules for enhanced vaccine potency.

Cytokine Gene Modification: Transduction with GM-CSF, IL-2, or IFN-gamma genes to recruit and activate APCs.
Costimulatory Molecule Expression: Introduction of CD80, CD86, or CD40L to provide direct T cell costimulation.
Chemokine Engineering: Expression of CCL3, CCL20, or CXCL10 to enhance DC and T cell migration.
Validation: Flow cytometry and ELISA confirmation of transgene expression and secretion levels.

Fusion

DC-Tumor Fusion Cell Vaccine Construction

Generating hybrid cells combining DC antigen-presenting capacity with the full tumor antigen repertoire.

Fusion Protocol: Polyethylene glycol (PEG)-mediated or fusogenic membrane glycoprotein-based DC-tumor cell fusion.
Fusion Verification: Dual-fluorescence staining and flow cytometry for fusion efficiency assessment.
HSP-Enriched Preparations: Isolation of HSP70 peptide complexes from fusion cells with elevated antigen cargo.
Functional Validation: IFN-gamma ELISpot and mixed lymphocyte reaction to confirm T cell activation capacity.

Formulation

Adjuvant Screening & Vaccine Formulation

Optimizing immunostimulatory adjuvants and delivery systems to maximize undefined antigen vaccine potency.

TLR Agonists: Screening of poly(I:C) (TLR3), LPS derivatives (TLR4), imiquimod (TLR7), and CpG oligonucleotides (TLR9).
Saponin-Based Adjuvants: QS-21 and haemocyanin carriers for Th1 and CD8+ T cell activation.
Delivery Systems: Liposome encapsulation, biodegradable nanoparticles, and oil-based emulsions for sustained antigen release.
Combination Optimization: Systematic adjuvant-antigen pairing to balance potency with safety in preclinical models.

Efficacy

Immunogenicity & Efficacy Evaluation

Comprehensive preclinical assessment of vaccine-induced antitumor immune responses and therapeutic efficacy.

In Vitro Assays: DC-T coculture, IFN-gamma ELISpot, intracellular cytokine staining (ICS), and proliferation assays.
In Vivo POC: Prophylactic and therapeutic tumor challenge studies in syngeneic and humanized mouse models.
Immune Profiling: TIL analysis by flow cytometry, cytokine multiplex, and TCR repertoire sequencing.
Combination Studies: Evaluation with immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) for synergistic efficacy.

Quality

QC & Data Package

Rigorous quality assurance and comprehensive data documentation for translational research.

Antigen Characterization: Protein quantification, HSP content verification (western blot), and exosome marker profiling (CD9, CD63, CD81).
Potency Assays: DC maturation markers (CD80, CD83, CD86, HLA-DR) and T cell activation readouts.
Sterility & Safety: Endotoxin testing, mycoplasma screening, and pathogen detection for cell products.
Full Data Report: Comprehensive documentation of preparation parameters, quality metrics, and efficacy outcomes.

Preclinical Undefined Antigen Vaccine Development Workflow

Phase 1 — Tumor Cell Sourcing & Antigen Preparation

Autologous or allogeneic tumor cells are sourced and processed into the appropriate undefined antigen format. Options include whole irradiated cells, freeze-thaw or sonication-derived lysates, oncolysates generated via lytic viruses, HSP-peptide complex purification, or tumor-derived exosome isolation. Protein content is quantified and antigen integrity verified.

Phase 2 — Immunogenic Cell Conditioning & DAMP Enrichment

Tumor cells or lysates undergo stress conditioning to enhance immunogenicity. Heat shock treatment induces calreticulin surface exposure, HMGB1 release, and HSP70 upregulation, providing endogenous danger signals. Alternative conditioning includes hypochlorous acid oxidation for oxidative stress or irradiation for immunogenic cell death induction, generating DAMPs that serve as natural adjuvants for DC activation.

Phase 3 — Dendritic Cell Loading & Fusion Cell Construction

Prepared antigen material is loaded onto autologous DCs via pulsing (lysates, HSP complexes, exosomes) or electroporation (tumor-derived mRNA). For DC-tumor fusion vaccines, PEG-mediated or fusogenic glycoprotein-based fusion generates hybrid cells that combine the antigen-processing machinery of DCs with the complete antigen repertoire of tumor cells. Loading efficiency and DC maturation status are validated by flow cytometry.

Phase 4 — Adjuvant Integration & Final Formulation

Adjuvants are selected and optimized to complement the antigen source. TLR agonists (CpG, poly(I:C), imiquimod), saponin-based adjuvants (QS-21), haemocyanin carriers, and nanoparticle delivery systems are evaluated. The final vaccine formulation is assembled with the appropriate delivery vehicle (liposomes, biodegradable nanoparticles, or oil-based emulsions) and stability is assessed.

Phase 5 — Comprehensive Immunogenicity & Efficacy Validation

Vaccine candidates undergo rigorous in vitro and in vivo evaluation. DC-T coculture assays and ELISpot confirm T cell activation. Syngeneic or humanized mouse models assess prophylactic and therapeutic efficacy, including tumor growth inhibition, survival benefit, and TIL profiling. Combination studies with immune checkpoint inhibitors evaluate synergistic potential for translational development.

Enabling Technologies for High-Potency Undefined Antigen Vaccines

ICD-Enhanced Antigen Conditioning

Controlled induction of immunogenic cell death (heat shock, HOCl oxidation, irradiation) transforms tumor cells into potent immunogens by triggering DAMP release—calreticulin surface exposure, ATP secretion, and HMGB1 release—providing natural adjuvanticity that drives DC maturation and cross-priming.

DC-Tumor Fusion Cell Platform

Hybrid cells generated by fusing DCs with whole tumor cells combine the full antigen-processing and presentation machinery of professional APCs with the complete antigen repertoire of tumor cells, achieving coordinated MHC-I and MHC-II presentation for simultaneous CD4+ and CD8+ T cell activation.

HSP-Exosome Dual Delivery

Tumor-derived exosomes carrying HSP70 and native tumor antigens provide a cell-free vaccine platform that activates DCs via TLR signaling (NF-kB pathway) and delivers pre-processed antigenic peptides for efficient cross-presentation, overcoming the need for live cell handling.

Why Choose Creative Biolabs?

Comprehensive Antigen Format Coverage

From whole tumor cells and lysates to HSP complexes, exosomes, and fusion cells—we support every undefined antigen format, selecting the optimal strategy for your tumor model and research goals.

ICD-Optimized Immunogenicity

Our tumor conditioning protocols are designed to maximize DAMP release and adjuvanticity, ensuring that undefined antigen preparations actively drive DC maturation rather than passively delivering antigens.

Flexible Modular Design

Each service module can be engaged independently or as part of an integrated pipeline, allowing researchers to select specific capabilities—from antigen preparation alone to full end-to-end development.

Rigorous Preclinical Validation

Every vaccine candidate undergoes thorough immunogenicity and efficacy testing with standardized readouts, providing the data foundation needed for informed translational decisions.

Research Insight: In Vivo Vaccination with Cell Line-Derived Whole Tumor Lysates – Neoantigen Quality Outranks Quantity

Key Preclinical Discoveries from the MMR-D Mlh1^-/- Tumor Model

The preclinical study conducted by Salewski et al. (2020) provides a detailed side-by-side comparison of two autologous cell line-derived whole tumor lysates in the mismatch repair-deficient (Mlh1^-/-) mouse model—resembling human Lynch syndrome. By evaluating two lysates with significantly different tumor mutational burdens (TMB)—the ultra-hypermutated 328 line (167 mutations/Mb) and the moderately mutated A7450 T1 M1 line (27 mutations/Mb)—the research reveals that the quality of neoantigens, rather than their sheer quantity, governs the therapeutic and prophylactic efficacy of cancer vaccines:

Disparity in Basal Cytokine Secretion Profiles: The moderately mutated A7450 T1 M1 cell line basally secretes elevated levels of immunostimulatory cytokines—including GM-CSF, IL-1β, and IL-18—which enhance natural killer (NK) cell cytotoxicity and drive protective helper Th1 cell polarization. Conversely, the ultra-hypermutated 328 line exhibits a prototypic immunosuppressive signature, secreting elevated levels of chemokines (MCP-1, MCP-3, and Eotaxin) associated with myeloid-derived suppressor cell (MDSC) recruitment.
Superior Prophylactic Protection & Elevated NK Activity: Repetitive prophylactic vaccination of mice with A7450 T1 M1 lysate achieved significantly prolonged cancer-free survival, extending median overall survival to 37 weeks, compared to 25 weeks for the 328 lysate and 22 weeks for untreated controls (p < 0.001). This survival benefit was accompanied by a marked expansion of circulating NK cells capable of recognizing autologous tumor targets and secreting IFN-γ in ELISpot assays.
Synergistic Antitumor Efficacy with Low-Dose Chemotherapy: Under therapeutic conditions, the A7450 T1 M1 vaccine prolonged survival to a median of 11 weeks and induced significant splenocyte activation. Sequential combination with low-dose Gemcitabine chemotherapy dramatically enhanced tumor growth control for both lysates, leading to stable disease and partial tumor remissions while significantly depleting systemic and splenic immunosuppressive MDSCs.
TME Remodeling & Immune Checkpoint Avoidance: Cryostat immunofluorescence revealed that successful immunization with the A7450 T1 M1 vaccine completely remodeled the tumor microenvironment (TME), suppressing the infiltration of CD11b⁺/Gr1⁺ MDSCs and F4/80⁺ tumor-associated macrophages (TAMs) while enriching tumors with CD11c⁺ DCs and CD8⁺ CTLs. In contrast, failed vaccine treatments (particularly 328) led to aggressive tumor infiltration by TAMs and a robust upregulation of immune checkpoint molecules LAG-3 and PD-L1 on intratumoral lymphocytes, whereas long-term responders avoided checkpoint expression entirely.

Murine treatment scheme of tumor lysate and gemcitabine administration.

Fig.1 https://no1.img.hicloudapp.net/downimage.php?id=1607&part=5-5-3-2-4-3-whole-tumor-lysate-dc-vaccine-construction-and-fusion-platform-2604-2.jpg.^{1, 2}

FAQs Regarding Undefined Antigen-Based Vaccine Services

We support a full range of undefined antigen formats: whole irradiated tumor cells (autologous or allogeneic), tumor cell lysates (freeze-thaw, sonication, oncolysate), heat shock protein-peptide complexes (gp96, HSP70), tumor-derived exosomes, and DC-tumor fusion cells. Each format has distinct immunological advantages, and we can help you select the optimal approach based on your tumor type and study objectives.

Unconditioned tumor lysates often lack sufficient danger signals for effective DC activation. Conditioning through heat shock, hypochlorous acid treatment, or controlled irradiation induces immunogenic cell death (ICD), triggering the release of DAMPs such as calreticulin, HMGB1, and ATP. These molecules serve as natural adjuvants that promote DC maturation, antigen uptake, and cross-priming, significantly enhancing vaccine immunogenicity compared to unconditioned lysate preparations.

Yes. We prepare undefined antigen vaccines for syngeneic mouse models (using mouse tumor cell lines and bone marrow-derived DCs) and for human systems (using patient-derived or allogeneic tumor cells with monocyte-derived DCs). Our humanized mouse models enable evaluation of human-specific immune responses to undefined antigen preparations in an in vivo setting.

Adjuvant selection depends on the antigen format and tumor type. For whole cell or lysate vaccines, TLR agonists (CpG for TLR9, poly(I:C) for TLR3, imiquimod for TLR7) and saponin-based QS-21 are commonly used to enhance Th1 and CD8+ T cell responses. For DC-loaded vaccines, the DAMPs inherent in ICD-conditioned preparations often provide intrinsic adjuvanticity, though we may supplement with haemocyanin carriers or cytokine adjuvants (GM-CSF) depending on the formulation strategy.

DC-tumor fusion cells combine the entire antigen-processing and co-stimulatory machinery of professional APCs with the complete antigen repertoire of tumor cells in a single hybrid cell. Unlike lysate-pulsed DCs, where antigens must be taken up and processed ex vivo, fusion cells continuously synthesize and present tumor antigens endogenously through both MHC-I and MHC-II pathways, providing sustained and coordinated CD4+ and CD8+ T cell activation. HSP70 peptide complexes isolated from fusion cells also carry elevated tumor antigen cargo compared to those from unfused cells.

Related Resources

Whole Tumor Lysate DC Vaccine Construction & Fusion Platform